INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 431m ago
HOUSE PTR31m ago
SEC 13F31m ago
ROBINHOOD CHAIN31m ago
SEC FORM 4/GiftVerified data

Watts Ryan J. reported DNLI

Director, President and CEO · Denali Therapeutics Inc. · Common Stock

Side
G
Value
—
Shares
32.2K
Price
—
Executed
Aug 12, 2026
Disclosed
Aug 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Aug 12 executedAug 14, 2026 disclosed

DNLI · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type+3 / 20

    Gift

  • Relative size+1 / 25

    No reported dollar value · 1.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DNLI

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    32
    CS
    Chin Peter ScottChief Medical Officer
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$37K
    1,654 sh
    		Sep 4, 2026Sep 9, 2026
    traded Sep 4, 2026
    		+5dSEC FORM 4

    Evidence

    10
    TN
    Thornberry NancyDirector
    DNLIDenali Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$15K
    615 sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    TN
    Thornberry NancyDirector
    DNLIDenali Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$247K
    10.8K sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    20
    SO
    Schuth Alexander O.COFO and Secretary
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$72K
    2,857 sh
    		Aug 11, 2026Aug 13, 2026
    traded Aug 11, 2026
    		+2dSEC FORM 4

    Evidence

    36
    SO
    Schuth Alexander O.COFO and Secretary
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$284K
    17.2K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    36
    WJ
    Watts Ryan J.Director, President and CEO
    DNLIDenali Therapeutics Inc.
    Open-market sale
    		SELL$581K
    35.2K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    VT
    Van Hauwermeiren TimothyDirector
    DNLIDenali Therapeutics Inc.
    Grant or award
    		A—
    31.9K sh
    		Nov 4, 2025Nov 6, 2025
    traded Nov 4, 2025
    		+2dSEC FORM 4

    Evidence

    9
    VT
    Van Hauwermeiren TimothyDirector
    DNLIDenali Therapeutics Inc.
    Grant or award
    		A—
    10.6K sh
    		Nov 4, 2025Nov 6, 2025
    traded Nov 4, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001724310-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 12, 2026
    Published
    Aug 14, 2026
    Ingested by INSIDER
    Nov 5, 02:22 UTC
    Last re-read
    Nov 5, 02:22 UTC

    Extracted facts

    Filer
    Watts Ryan J.
    Role
    Director, President and CEO
    Transaction
    GiftAs filed: “G”
    Asset
    Denali Therapeutics Inc.
    Ticker
    DNLI
    Shares
    32.2K
    Price per share
    $0
    Execution date (reported)
    Aug 12, 2026
    Owned after transaction
    2.12M shares
    Days from execution to publication
    2

    What this establishes

    Watts Ryan J. filed this Form 4 reporting a gift of DNLI on Aug 12, 2026. It became public on Aug 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and CEO
    Watts Ryan J.cik:0001724310
    Issuer
    Denali Therapeutics Inc.cik:0001714899

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.